Phosphate

  Healio spoke with Kevin Martin, MD, professor of medicine and director of the division of nephrology at Saint Louis University School of Medicine, about the challenges of managing hyperphosphatemia, prevention measures to recommend to patients at high risk for developing the condition, unmet needs in hyperphosphatemia management and more.

  Healio spoke with Kevin Martin, MD, professor of medicine and director of the division of nephrology at Saint Louis University School of Medicine, about the challenges of managing hyperphosphatemia, prevention measures to recommend to patients at high risk for developing the condition, unmet needs in hyperphosphatemia management and more.

  Healio spoke with Kevin Martin, MD, professor of medicine and director of the division of nephrology at Saint Louis University School of Medicine, about the challenges of managing hyperphosphatemia, prevention measures to recommend to patients at high risk for developing the condition, unmet needs in hyperphosphatemia management and more.

  Healio spoke with Kevin Martin, MD, professor of medicine and director of the division of nephrology at Saint Louis University School of Medicine, about the challenges of managing hyperphosphatemia, prevention measures to recommend to patients at high risk for developing the condition, unmet needs in hyperphosphatemia management and more.

  Healio spoke with Kevin Martin, MD, professor of medicine and director of the division of nephrology at Saint Louis University School of Medicine, about the challenges of managing hyperphosphatemia, prevention measures to recommend to patients at high risk for developing the condition, unmet needs in hyperphosphatemia management and more.

Food products in the United States often include phosphate content but it is rare that the addition is described for consumers, according to data published in the Journal of Renal Nutrition.

Compared with patients in European countries and Japan, patients using in-center hemodialysis in the United States showed a significant increase in serum phosphorous levels , according to data published in Kidney Medicine.

Ardelyx Inc. has been granted an appeal to a complete response letter issued last year by the FDA regarding the company’s new drug application for its phosphate absorption inhibitor drug Xphozah.

An FDA advisory committee voted 9-4 in favor of the use of Xphozah as a monotherapy for controlling serum phosphorus levels in adults with chronic kidney disease on dialysis.

Researchers have discovered a link between neurotoxicity related to chimeric antigen receptor T-cell therapy and development of subsequent hypophosphatemia.